4D Molecular Therapeutics, Inc. (FDMT)

Market Cap	168.08M
Revenue (ttm)	37,000
Net Income (ttm)	-160.87M
Shares Out	46.30M
EPS (ttm)	-2.98
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	616,236
Open	3.560
Previous Close	3.560
Day's Range	3.450 - 3.655
52-Week Range	3.450 - 31.870
Beta	2.82
Analysts	Buy
Price Target	35.00 (+864.19%)
Earnings Date	May 8, 2025

About FDMT

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherland and the United States. The company’s lead product candidate, 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with a single, safe, and intravitreal injection; and 4D-710 for the treatment of cystic fibrosis through early-stage studies. ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 147
• Stock Exchange: NASDAQ
• Ticker Symbol: FDMT

Financial Performance

In 2024, 4D Molecular Therapeutics's revenue was $37,000, a decrease of -99.82% compared to the previous year's $20.72 million. Losses were -$160.87 million, 59.5% more than in 2023.

Analyst Forecast

According to 10 analysts, the average rating for FDMT stock is "Buy." The 12-month stock price forecast is $35.0, which is an increase of 864.19% from the latest price.

Price Target

$35.0

(864.19% upside)

Analyst Consensus: Buy